Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care

Figures & data

Table I. Characteristics of study population in %.

	ASD users (n = 977)	ASD users in the reduction programme (n = 188)
Gender
Male	40.7	41.7
Age
25–54	25.6	30.1
55–74	51.9	47.7
75+	22.3	22.5
ASD prescribed by^a
GP	66.7	87.5
Specialist	29.1	10.9
Other	4.2	1.6
Education level
Low	64.7	63.3
Moderate	25.4	28.3
High	9.5	8.3
General health^b
Very good	5.9	11.4
Good	39.6	45.1
Acceptable	45.1	36.4
Bad	9.4	7.1
Antacid use
PPI	82.1	79.3
H2RA	17.9	20.7
Endoscopy	21.4	19.6
Health compared to the previous year
Better	16.3	20.0
Same	54.1	56.2
Worse	29.6	23.8

^aP <0.001.

^bP <0.01.

ASD, acid-suppressing drug.

Figure 1. Diagram of respondents with chronic ASD use and the number that participated or did not in the ASD reduction programme

Table II. Experience and importance scores of patients on ASD that participated in the reduction programme and the quality impact indices on the three scales. (n = 173).

	Experience	Importance	Improvement
	score^a	score^b	score^c
Quality of GP support during the intervention	2.89	2.98	8.6
Communication by and conduct of the GP	1.52	3.23	4.9
Patient involvement in decisions	1.59	3.25	5.2

^a1 = very good experience, 4 = very bad experience.

^b1 = not important, 4 = of the utmost importance.

^cMaximum score is 16.

ASD, acid-suppressing drugs